Renaissance Technologies LLC Has $5.21 Million Stake in LivaNova PLC (NASDAQ:LIVN)

Renaissance Technologies LLC boosted its stake in shares of LivaNova PLC (NASDAQ:LIVN - Free Report) by 9.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 112,594 shares of the company's stock after purchasing an additional 9,500 shares during the quarter. Renaissance Technologies LLC owned about 0.21% of LivaNova worth $5,214,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Russell Investments Group Ltd. boosted its holdings in shares of LivaNova by 17.1% during the 4th quarter. Russell Investments Group Ltd. now owns 1,502 shares of the company's stock worth $70,000 after buying an additional 219 shares during the period. Central Pacific Bank Trust Division lifted its position in LivaNova by 21.2% during the fourth quarter. Central Pacific Bank Trust Division now owns 4,117 shares of the company's stock worth $191,000 after acquiring an additional 720 shares during the last quarter. Sanctuary Advisors LLC bought a new stake in shares of LivaNova during the third quarter worth approximately $219,000. Vestcor Inc acquired a new position in shares of LivaNova in the fourth quarter valued at approximately $204,000. Finally, Inceptionr LLC acquired a new stake in LivaNova during the 4th quarter worth approximately $217,000. 97.64% of the stock is currently owned by institutional investors and hedge funds.

LivaNova Price Performance

Shares of NASDAQ LIVN traded up $0.87 during trading hours on Wednesday, hitting $36.33. 590,173 shares of the stock were exchanged, compared to its average volume of 626,024. LivaNova PLC has a 1-year low of $32.48 and a 1-year high of $64.48. The company has a market cap of $1.97 billion, a PE ratio of 86.50 and a beta of 0.90. The company has a debt-to-equity ratio of 0.46, a quick ratio of 2.87 and a current ratio of 3.37. The company's fifty day simple moving average is $39.58 and its two-hundred day simple moving average is $46.46.

Analysts Set New Price Targets

Several research firms have weighed in on LIVN. Mizuho lowered their price objective on LivaNova from $70.00 to $60.00 and set an "outperform" rating on the stock in a research report on Wednesday, February 26th. The Goldman Sachs Group cut their price objective on shares of LivaNova from $64.00 to $55.00 and set a "buy" rating for the company in a report on Monday, March 3rd. Stifel Nicolaus lowered their target price on shares of LivaNova from $72.00 to $60.00 and set a "buy" rating on the stock in a report on Wednesday, February 26th. Barclays dropped their price target on shares of LivaNova from $58.00 to $56.00 and set an "equal weight" rating for the company in a research report on Friday, March 7th. Finally, Needham & Company LLC restated a "buy" rating and set a $64.00 price objective on shares of LivaNova in a research note on Monday, March 17th. Two research analysts have rated the stock with a hold rating, five have issued a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, LivaNova presently has an average rating of "Buy" and a consensus target price of $61.17.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.